SEC Filing Summary: Zapata Corporation (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1999, for Zapata Corporation. The Company changed its fiscal year-end from September 30 to December 31 effective January 1, 1999. Zapata is a holding company primarily owning approximately 61% of Omega Protein Corporation (marine protein products), approximately 40% of Viskase Companies, Inc. (food packaging), and approximately 98% of ZAP.COM Corporation (Internet development). The financial statements are unaudited.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1999 | Nine Months Ended Sep 30, 1998 |
|---|---|---|---|
| Revenues | $23.7 million | $64.1 million | $104.1 million |
| Net (Loss) Income | ($7.9) million | ($9.4) million | $64.3 million |
| Operating (Loss) Income | ($18.6) million | ($18.9) million | $22.3 million |
| Cash and Equivalents | $115.6 million (Sep 30, 1999) | Down from $154.7 million (Dec 31, 1998) | |
| Working Capital | $168.2 million (Sep 30, 1999) | Down from $194.1 million (Dec 31, 1998) | |
| Long-Term Debt | $10.7 million | Current maturities: $0.7 million | |
| EPS (Basic) | ($0.33) | ($0.40) | $2.80 |
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped 44.2% in the quarter and 38.4% for the nine months compared to 1998. This was driven by a 32% decline in fish meal prices and a 65% decline in fish oil prices, despite relatively stable sales volumes.
- Inventory Writedown: Omega Protein recorded a non-cash inventory writedown of $14.5 million due to market prices falling below cost basis. This charge significantly impacted operating income.
- Profitability Shift: The Company swung from a net income of $64.3 million in the prior nine-month period (boosted by an $86.7 million gain on the sale of Omega Protein stock) to a net loss of $9.4 million.
- Cash Flow: Operating activities used $24.7 million in cash for the nine months ended September 30, 1999, compared to providing $6.2 million in the prior year. This was primarily due to inventory buildup and the writedown.
- Viskase Investment: Zapata suspended recording equity losses from Viskase after its investment was reduced to zero due to Viskase's restructuring charges in late 1998.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur net losses for the foreseeable future due to the operations of ZAP.COM and continued difficult market conditions for Omega Protein. Gross profit margins may continue to decline if prices do not recover or production costs exceed market value in the fourth quarter.
- Liquidity: Zapata believes existing cash ($115.6 million) is sufficient to meet requirements through the end of 2000. Omega Protein also expects its cash and credit facilities to be sufficient through 2000.
- Legal Contingencies:
- A state court judgment of approximately $3.45 million was entered against Zapata regarding a former employee's stock options. Zapata has appealed and believes it has a meritorious defense.
- A consolidated securities class action suit was dismissed with prejudice in September 1999.
- Year 2000 (Y2K): Zapata and Omega Protein report their critical systems are Y2K compliant. Zapata does not anticipate material adverse effects, though risks remain regarding third-party vendors and utilities.
- ZAP.COM Distribution: On November 12, 1999, Zapata distributed ZAP.COM stock to shareholders and contributed $9 million to the subsidiary. Zapata expects ZAP.COM to incur significant charges and losses.
Investor Verification Checklist
- Verify the sustainability of the $14.5 million inventory writedown and whether further write-downs are anticipated for the fourth quarter.
- Monitor the appeal of the $3.45 million litigation judgment and potential cash outflows if the appeal fails.
- Assess the impact of ZAP.COM's expected losses on consolidated earnings, given Zapata's 98% ownership.
- Review Omega Protein's pricing trends for fish meal and oil to determine if the 32-65% price declines are cyclical or structural.
- Confirm the status of Omega Protein's Title XI loan program and its ability to secure the remaining $5.6 million in authorized funding.